Cancer-fighting Five Prime Therapeutics Inc. will cut about 20 percent of its 209-person workforce as it tries to push more drugs into clinical trials and advance those already being tested on patients.
The move — the first large-scale layoff in the South San Francisco biotech company’s 17 years — comes during a sustained push by Five Prime (NASDAQ: FPRX) into cancer immunotherapy, where drugs are used to rally the immune system to battle cancer.
The job cuts, starting today, include research,…
